Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ARO-APOC3

Oligonucleotide (siRNA) · developed by ARROWHEAD PHARMACEUTICALS

Phase 2 Most advanced trial (none active)
ARWR Developer
1 Registered trials

What is ARO-APOC3?

ARO-APOC3 is an siRNA that silences apolipoprotein C-III (APOC3) to reduce triglyceride levels. It is studied in dyslipidemias.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Therapy area
Metabolic
Developer
ARROWHEAD PHARMACEUTICALS (ARWR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05413135 Phase 2 Dyslipidemias Completed ARWR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dyslipidemias

More from ARROWHEAD PHARMACEUTICALS

Plozasiran FDA approved ARC-521 Phase 1 ARC-AAT Phase 2 ARO-033 Phase 1 ARO-ALK7 Phase 1/2 ARO-ANG 3 Phase 2 ARO-ATXN2 Phase 1 ARO-C3 Phase 1/2 ARO-CFB Phase 1 ARO-DIMERPA Phase 1/2 ARO-ENaC Phase 1/2 ARO-HBV Phase 1/2

Follow ARWR, the company behind ARO-APOC3

See ARWR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARWR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.